TherapeuticsMD (NASDAQ:TXMD) Releases Quarterly Earnings Results, Beats Expectations By $6.16 EPS

TherapeuticsMD (NASDAQ:TXMD) posted its quarterly earnings data on Friday. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($6.12) by $6.16, FiscalAI reports. The business had revenue of $1.26 million during the quarter, compared to analysts’ expectations of $19.77 million. TherapeuticsMD had a negative return on equity of 1.09% and a negative net margin of 6.64%.

TherapeuticsMD Price Performance

NASDAQ TXMD traded up $0.05 during mid-day trading on Friday, hitting $1.87. The stock had a trading volume of 50,241 shares, compared to its average volume of 42,189. The firm’s 50 day moving average is $1.98 and its 200 day moving average is $2.09. The stock has a market capitalization of $21.64 million, a price-to-earnings ratio of 93.50 and a beta of 0.68. TherapeuticsMD has a twelve month low of $1.43 and a twelve month high of $2.95.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of TherapeuticsMD from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About TherapeuticsMD

TherapeuticsMD, Inc. was a pharmaceutical company focused on developing and commercializing products for women’s health. Its portfolio addressed contraception, menopause-related conditions, pregnancy-related nausea, and nutritional support, with products marketed primarily in the United States. The company’s principal products included ANNOVERA, a reusable, year-long vaginal contraceptive system; IMVEXXY, vaginal inserts containing estradiol for the treatment of moderate to severe vaginal symptoms associated with menopause; and BIJUVA, an oral hormone therapy combining estradiol and progesterone.